- Home
- XNCR vs DIAX Comparison
XNCR vs DIAX Comparison
Compare XNCR & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- DIAX
- Stock Information
- Founded
- XNCR 1997
- DIAX 2005
- Country
- XNCR United States
- DIAX United States
- Employees
- XNCR N/A
- DIAX N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- XNCR Health Care
- DIAX Finance
- Exchange
- XNCR Nasdaq
- DIAX Nasdaq
- Market Cap
- XNCR 579.3M
- DIAX 516.0M
- IPO Year
- XNCR 2013
- DIAX N/A
- Fundamental
- Price
- XNCR $7.90
- DIAX $14.31
- Analyst Decision
- XNCR Buy
- DIAX
- Analyst Count
- XNCR 7
- DIAX 0
- Target Price
- XNCR $27.50
- DIAX N/A
- AVG Volume (30 Days)
- XNCR 800.2K
- DIAX 96.6K
- Earning Date
- XNCR 08-04-2025
- DIAX 01-01-0001
- Dividend Yield
- XNCR N/A
- DIAX 7.93%
- EPS Growth
- XNCR N/A
- DIAX N/A
- EPS
- XNCR N/A
- DIAX N/A
- Revenue
- XNCR $127,228,000.00
- DIAX N/A
- Revenue This Year
- XNCR N/A
- DIAX N/A
- Revenue Next Year
- XNCR $28.84
- DIAX N/A
- P/E Ratio
- XNCR N/A
- DIAX N/A
- Revenue Growth
- XNCR N/A
- DIAX N/A
- 52 Week Low
- XNCR $7.16
- DIAX $12.80
- 52 Week High
- XNCR $27.24
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- XNCR 44.24
- DIAX 52.76
- Support Level
- XNCR $7.88
- DIAX $13.63
- Resistance Level
- XNCR $8.80
- DIAX $13.92
- Average True Range (ATR)
- XNCR 0.53
- DIAX 0.12
- MACD
- XNCR -0.05
- DIAX -0.00
- Stochastic Oscillator
- XNCR 22.41
- DIAX 64.06
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.